Skip to main navigation Skip to search Skip to main content

Safety and Efficacy of AAV2tYF-PR1.7-CNGA3 in CNGA3-deficient Sheep

  • Mark S. Shearman
  • , Elisha Gootwine
  • , Eyal Banin
  • , Ron Ofri
  • , Raaya Ezra-Elia
  • , Guo-jie Ye
  • , Paulette Robinson
  • , David Knop
  • , Jeffrey D. Chulay

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
Purpose : Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, extreme light sensitivity and absence of color discrimination. AGTC is developing AAV2tYF-PR1.7-CNGA3, a recombinant adeno-associated virus (rAAV) vector expressing CNGA3, for treatment of CNGA3-related achromatopsia. Here we report results of a toxicology and efficacy study of this vector administered by subretinal injection in CNGA3-deficient sheep.
Original languageEnglish
JournalInvestigative Ophthalmology and Visual Science
Volume58
Issue number8
StatePublished - Jun 2017

Fingerprint

Dive into the research topics of 'Safety and Efficacy of AAV2tYF-PR1.7-CNGA3 in CNGA3-deficient Sheep'. Together they form a unique fingerprint.

Cite this